{"transactions":[{"id":804266,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:23.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744682/000119312526164307/ownership.xml","form_type":"4"}},{"id":804265,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:23.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744682/000119312526164307/ownership.xml","form_type":"4"}},{"id":1753016,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:43:04.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":false,"shares":9418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":9417,"derivative":{"underlying":"Common Stock","underlying_shares":9418},"source":{"system":"sec-edgar","filing":"0000899243-23-020082","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020082/doc4.xml","form_type":"4"}},{"id":1753015,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T01:43:04.000Z","date":"2023-04-27","kind":"grant","planned":true,"acquired":true,"shares":18835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents a contingent right to receive one share of Issuer common stock.  The RSUs do not have an expiration date."}],"balance_after":18835,"derivative":{"underlying":"Common Stock","underlying_shares":18835},"source":{"system":"sec-edgar","filing":"0000899243-23-020082","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020082/doc4.xml","form_type":"4"}},{"id":1753014,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-01T01:43:04.000Z","date":"2023-10-30","kind":"sale","planned":true,"acquired":false,"shares":2904,"price":1.35,"value":3920.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in column 4 is a weighted average of the price.  These shares were sold in multiple transactions at prices ranging from $1.35 to $1.3614, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":45684,"source":{"system":"sec-edgar","filing":"0000899243-23-020082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020082/doc4.xml","form_type":"4"}},{"id":1753013,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-01T01:43:04.000Z","date":"2023-10-27","kind":"exercise","planned":true,"acquired":true,"shares":9418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 3, 2023, the reporting person was granted an award of 18,835 restricted stock units (\"RSUs\"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria.  On April 27, 2023 (the \"Initial Milestone Date\"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 9,418 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date.  The remaining 9,417 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 7,424 shares of common stock acquired under the Issuer's employee stock purchase plan."}],"balance_after":48588,"source":{"system":"sec-edgar","filing":"0000899243-23-020082","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323020082/doc4.xml","form_type":"4"}},{"id":2027989,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-07T22:42:15.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":95000,"derivative":{"exercise_price":5.5,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0000899243-23-004197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323004197/doc4.xml","form_type":"4"}},{"id":2027988,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-02-07T22:42:15.000Z","date":"2023-02-03","kind":"grant","acquired":true,"shares":47500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter."}],"balance_after":47500,"derivative":{"underlying":"Common Stock","underlying_shares":47500},"source":{"system":"sec-edgar","filing":"0000899243-23-004197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924323004197/doc4.xml","form_type":"4"}},{"id":2211308,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"COMMON STOCK","published_at":"2022-07-06T23:25:24.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":31746,"price":3.15,"value":99999.9,"ownership":{"direct":true},"balance_after":31746,"source":{"system":"sec-edgar","filing":"0000899243-22-025518","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322025518/doc4.xml","form_type":"4"}},{"id":2407854,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Options (right to buy)","published_at":"2022-02-09T02:35:30.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest and become exercisable as to 25% of the shares on February 7, 2023.  The remainder of the shares will vest and become exercisable in 12 equal quarterly installments thereafter."}],"balance_after":190000,"derivative":{"exercise_price":7.6,"expiration_date":"2032-02-06","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0000899243-22-005322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924322005322/doc4.xml","form_type":"4"}},{"id":3599422,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (right ot buy)","published_at":"2019-03-12T18:11:30.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023."}],"balance_after":60000,"derivative":{"exercise_price":7.95,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-19-018953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919119018953/doc4.xml","form_type":"4"}}]}